Related Experiment Video

Updated: Aug 11, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Rational drug therapy based on understanding the pathophysiology of hypertension

E L Bravo

    Cleveland Clinic Journal of Medicine
    |June 1, 1989
    PubMed

    Insights

    Chronic hypertension, marked by increased vascular resistance, can be effectively managed. Newer, targeted therapies allow for individualized, long-term monotherapy in specific patient subgroups.

    Area of Science:

    • Cardiovascular Physiology
    • Pharmacology
    • Nephrology

    Background:

    • Peripheral vascular resistance is a key characteristic of chronic hypertension.
    • Calcium ions (Ca2+) play a crucial role in vasoconstriction.
    • Hypertension can stem from various mechanisms including volume variations and neurogenic factors.

    Purpose of the Study:

    • To review the mechanisms of hypertension and their targeted pharmacological treatments.
    • To highlight the advancements in individualized therapy for hypertensive patients.
    • To discuss the potential for long-term monotherapy.

    Main Methods:

    • Review of current biochemical and pharmacological knowledge.
    • Analysis of cardiovascular physiology in hypertension.
    • Categorization of hypertensive patient subgroups based on underlying mechanisms.

    Main Results:

    • Calcium channel blockers address specific arteriolar vasoconstriction.
    • Diuretics are effective for hypertension related to volume variations.
    • Alpha- or beta-receptor blockers and converting enzyme inhibitors target neurogenic-mediated vasoconstriction.
    • Newer agents allow for specific and selective actions.

    Conclusions:

    • Rational and individualized therapy for hypertension is achievable.
    • Minimal drug dosages and monotherapy are possible for specific patient subgroups.
    • Advances in understanding hypertension facilitate more effective treatment strategies.

    More Related Videos

    Real-Time Monitoring and Modulation of Blood Pressure in a Rabbit Model of Ischemic Stroke09:00

    Real-Time Monitoring and Modulation of Blood Pressure in a Rabbit Model of Ischemic Stroke

    Published on: February 10, 2023

    The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension05:57

    The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

    Published on: May 17, 2024

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    Hypertension II: Pathophysiology01:29

    Hypertension II: Pathophysiology

    Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
    Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

    Hypertension IV: Drug Therapy and Lifestyle Modifications

    Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...